🇺🇸 FDA
Pipeline program

lymphokine-activated killer cells

CDR0000630437

Phase 2 mab terminated

Quick answer

lymphokine-activated killer cells for Brain and Central Nervous System Tumors is a Phase 2 program (mab) at LISATA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
LISATA THERAPEUTICS, INC.
Indication
Brain and Central Nervous System Tumors
Phase
Phase 2
Modality
mab
Status
terminated

Clinical trials